Plasma concentrations of three major vitamin D3 metabolites, 25-hydroxyvitamin D3 (25-OHD3), 24R, 25-dihydroxyvitamin D3 (24,25-(OH)2D3), and 1 alpha, 25-dihydroxyvitamin D3 (1,25-(OH)2D3), were determined serially in patients with gynecological malignancies treated by chemotherapy which included cisplatin. While 25-OHD3 and 24,25-(OH)2D3 levels did not change regularly, 1,25-(OH)2D3 decreased significantly (50%) after only one or two courses of the treatment in all cases. In concert with declining 1,25-(OH)2D3, the PTH levels increased two or three times. The results were explained by the impairment by cisplatin of mitochondrial function in proximal tubules in the kidney.
No takes yet. Share an insight, caveat, or question.
Gao et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: